How India Exports Voriconazole to the World

In the United States, voriconazole is approved under the brand name Vfend, with multiple generic versions available. The FDA's Orange Book lists several approved Abbreviated New Drug Applications (ANDAs) for voriconazole, indicating a competitive generic market. Notably, in November 2025, the FDA approved ANDA 220043 for Voriconazole Injection, 200 mg/20 mL (10 mg/mL) Single-Dose Vial, submitted by Hainan Poly Pharm. Co., Ltd. This approval underscores the ongoing interest in voriconazole within the U.S. market.

Given that 18.6% of India's voriconazole exports are directed to the United States, it is imperative for Indian exporters to ensure compliance with FDA regulations, including adherence to Good Manufacturing Practices (GMP) and the Drug Supply Chain Security Act (DSCSA). The presence of 144 active Indian exporters highlights the competitive nature of this market segment.

In the European Union, voriconazole is marketed under the brand name Vfend, with Pfizer Europe MA EEIG holding the marketing authorization since March 2002. (ema.europa.eu) Generic versions, such as Voriconazole Accord, received marketing authorization in May 2013. (ema.europa.eu) The European Medicines Agency (EMA) oversees the approval process, ensuring compliance with EU GMP requirements.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates voriconazole. Post-Brexit, the UK has established its own regulatory framework, though it remains aligned with EU standards in many aspects. Indian exporters targeting the UK market must ensure compliance with MHRA guidelines and may need to appoint a UK-based representative.

Voriconazole is included in the World Health Organization's Model List of Essential Medicines, recognizing its importance in treating serious fungal infections. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, voriconazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, voriconazole is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with export regulations.

The primary patents for voriconazole have expired, leading to increased generic competition globally. This has resulted in a more competitive market, with multiple manufacturers producing and exporting the drug.

In December 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending changes to the marketing authorization for Vfend, including updates to contraindications and co-administration guidelines. (ema.europa.eu)

In November 2025, the FDA approved ANDA 220043 for Voriconazole Injection, 200 mg/20 mL (10 mg/mL) Single-Dose Vial, submitted by Hainan Poly Pharm. Co., Ltd., indicating ongoing interest in voriconazole within the U.S. market.

In October 2025, the EMA updated the product information for Voriconazole Accord, reflecting changes in manufacturing processes and other regulatory updates. (ema.europa.eu)

In September 2025, the EMA's CHMP adopted a positive opinion recommending changes to the marketing authorization for Norvir, including updates to indications and contraindications. (ema.europa.eu)

In August 2025, the EMA's CHMP adopted a positive opinion recommending changes to the marketing authorization for Cresemba, including updates to indications and contraindications. (ema.europa.eu)

These developments underscore the dynamic regulatory environment surrounding voriconazole and the importance of staying informed about changes that may impact market access and compliance requirements.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 70% of India's APIs and KSMs are imported from China, creating a significant dependency. This reliance poses risks, as disruptions in Chinese supply chains can lead to shortages and increased costs for Indian manufacturers.

In response, the Indian government has initiated the Production Linked Incentive (PLI) scheme to bolster domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid, aiming to reduce import dependence by half.

The top five exporters of Voriconazole from India hold a combined market share of 63.6%, with SANDOZ PRIVATE LIMITED leading at 27.1%. This concentration indicates a potential risk, as disruptions affecting these key suppliers could significantly impact global supply. The PLI scheme, launched in 2020, aims to mitigate such risks by promoting diversification and enhancing domestic manufacturing capabilities. However, the effectiveness of this initiative in reducing supplier concentration remains to be fully realized.

Recent geopolitical tensions have severely impacted global shipping routes. In March 2026, the Strait of Hormuz was blocked due to escalating conflicts, leading to a near halt in maritime traffic and affecting approximately 20% of the world's daily oil supply. This disruption has had cascading effects on global trade, including the pharmaceutical supply chain. (lemonde.fr)

Additionally, the Red Sea has experienced increased instability, with attacks on vessels leading to rerouting of shipments around Africa's Cape of Good Hope. These disruptions have resulted in increased shipping costs and delays, further straining the supply chain for pharmaceuticals like Voriconazole. (lemonde.fr)

• Diversify Supplier Base: Encourage the development of alternative suppliers for APIs and KSMs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to boost local manufacturing of critical pharmaceutical ingredients.

• Strengthen Supply Chain Resilience: Develop contingency plans and maintain strategic reserves to buffer against geopolitical and shipping disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical risks that could impact the pharmaceutical supply chain.

• Invest in Logistics Infrastructure: Improve domestic logistics capabilities to reduce reliance on vulnerable international shipping routes.

RISK_LEVEL: HIGH